Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05154890 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency
A Phase 1 study, sponsored by Aeglea Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05154890 is a Phase 1 study that was terminated before completion, run by Aeglea Biotherapeutics. The registered enrollment target is 13 participants.
The verdict
NCT05154890, a Phase 1 study, was terminated before completion, sponsored by Aeglea Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of pegtarviliase in approximately 36 subjects with homocystinuria due to CBS deficiency.
Interventions
- DRUG Pegtarviliase IV
- DRUG Pegtarviliase SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-13 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05154890
The ClinicalTrials.gov registry entry for NCT05154890 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aeglea Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pegtarviliase IV is the first listed.
NCT05154890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05154890 about?
NCT05154890 is a clinical study titled "A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency". The purpose of this study is to evaluate the safety and tolerability of pegtarviliase in approximately 36 subjects with homocystinuria due to CBS deficiency.
What is the current status of trial NCT05154890?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-05-13. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT05154890?
The interventions under investigation include: Pegtarviliase IV (DRUG), Pegtarviliase SC (DRUG).
Who is sponsoring clinical trial NCT05154890?
This trial is sponsored by Aeglea Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.